Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT vs CRT Boost for High Risk Prostate Cancer
NCT03380806Phase 2Unknown
- Sponsor
- Juravinski Cancer Centre
- Start
- Jan 2019
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Juravinski Cancer Centre. Primary endpoint: Short Term Quality of Life at 6 months. Status: unknown.
Beyond the preview
Go deeper on NCT03380806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380806.